More recently, topical PDE4 inhibitors such as crisaborole and difamilast have expanded therapeutic options for mild-to-moderate AD, while topical roflumilast has been approved for plaque psoriasis and seborrheic dermatitis. Here, PDE4A is linked to psoriasis vulgaris.